Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1985]
News [3223]
Articles [134]
Editorials [3]
Conferences [121]
elearning [18]
ASH 2024: Longer-term data for asciminib reinforce superior efficacy with favourable safety and tolerability profile in adults with newly diagnosed CML
ASH 2024: Longer-term data for asciminib reinforce superior efficacy with favourable safety and tolerability...
ASH 2O24: Early signs of efficacy for a novel drug and a new predictive tool to guide patient care
ASH 2O24: Early signs of efficacy for a novel drug and a new predictive tool to guide patient care
ASH 2024: Study finds genetic changes, elevated leukaemia risk in ground zero first responders
ASH 2024: Study finds genetic changes, elevated leukaemia risk in ground zero first responders
ASH 2024: Prospective study finds social and economic factors limit access to stem cell transplants for patients with AML
ASH 2024: Prospective study finds social and economic factors limit access to stem cell transplants for patients...
ASH 2024: High response rate, manageable adverse effects seen with epcoritamab in pretreated R/R CLL
ASH 2024: High response rate, manageable adverse effects seen with epcoritamab in pretreated R/R CLL
ASH 2024 - Multi-center study shows education level, income impact access to stem cell transplantation for acute myeloid leukaemia patients
ASH 2024 - Multi-center study shows education level, income impact access to stem cell transplantation for acute...
ASH 2024: Combining BCL-2 and BTK inhibitors shows promise in CLL
ASH 2024: Combining BCL-2 and BTK inhibitors shows promise in CLL
ASH 2024: Anitocabtagene autoleucel demonstrates 97% ORR and 62% CR/sCR in relapsed or refractory multiple myeloma
ASH 2024: Anitocabtagene autoleucel demonstrates 97% ORR and 62% CR/sCR in relapsed or refractory multiple myeloma
ASH 2024: Combination of two oral agents improves progression-free survival in previously untreated chronic lymphocytic leukaemia
ASH 2024: Combination of two oral agents improves progression-free survival in previously untreated chronic...
ASH 2024: Belantamab mafodotin shows significant OS benefit, reducing risk of death by 42% in multiple myeloma at or after first relapse
ASH 2024: Belantamab mafodotin shows significant OS benefit, reducing risk of death by 42% in multiple myeloma at...

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation